NO943526L - Kinuklidin-derivater som substans P antagonister - Google Patents

Kinuklidin-derivater som substans P antagonister

Info

Publication number
NO943526L
NO943526L NO943526A NO943526A NO943526L NO 943526 L NO943526 L NO 943526L NO 943526 A NO943526 A NO 943526A NO 943526 A NO943526 A NO 943526A NO 943526 L NO943526 L NO 943526L
Authority
NO
Norway
Prior art keywords
alkyl
substituted
alkoxy
hydrogen
disorders
Prior art date
Application number
NO943526A
Other languages
English (en)
Other versions
NO943526D0 (no
Inventor
Kunio Satake
Hiroaki Wakabayashi
Masami Nakane
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO943526D0 publication Critical patent/NO943526D0/no
Publication of NO943526L publication Critical patent/NO943526L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
NO943526A 1992-03-23 1994-09-22 Kinuklidin-derivater som substans P antagonister NO943526L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6533792 1992-03-23
PCT/US1993/001810 WO1993019064A1 (en) 1992-03-23 1993-03-05 Quinuclidine derivatives as substance p antagonists

Publications (2)

Publication Number Publication Date
NO943526D0 NO943526D0 (no) 1994-09-22
NO943526L true NO943526L (no) 1994-09-22

Family

ID=13284021

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943526A NO943526L (no) 1992-03-23 1994-09-22 Kinuklidin-derivater som substans P antagonister

Country Status (18)

Country Link
EP (1) EP0632809B1 (no)
JP (1) JP2656702B2 (no)
KR (1) KR950700908A (no)
AT (1) ATE205207T1 (no)
AU (1) AU3782493A (no)
CA (1) CA2132541C (no)
DE (1) DE69330714T2 (no)
DK (1) DK0632809T3 (no)
ES (1) ES2160596T3 (no)
FI (1) FI944394A (no)
GR (1) GR3037025T3 (no)
HU (1) HU9402745D0 (no)
IL (1) IL105098A0 (no)
MX (1) MX9301634A (no)
NO (1) NO943526L (no)
PT (1) PT632809E (no)
WO (1) WO1993019064A1 (no)
ZA (1) ZA932016B (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
ATE171945T1 (de) * 1993-07-15 1998-10-15 Pfizer Benzyloxychinuclidine als substanz p antagonisten
DK0719253T3 (da) * 1993-09-17 2004-07-26 Pfizer 3-amino-5-carboxy-substituerede piperidiner og 3-amino-4-carboxy-substituerede pyrrolidiner som tachykininantagonister
US6083943A (en) * 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0659409A3 (en) * 1993-11-23 1995-08-09 Pfizer Substance P antagonists for the inhibition of angiogenesis.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
AU781179B2 (en) 1999-11-03 2005-05-12 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
US20040001895A1 (en) * 2002-06-17 2004-01-01 Pfizer Inc. Combination treatment for depression and anxiety
EP1778639B1 (en) 2004-07-15 2015-09-02 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
KR20080044840A (ko) 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CA2717509A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
MX2012004377A (es) 2009-10-14 2012-06-01 Merck Sharp & Dohme Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
JP6290237B2 (ja) 2012-11-28 2018-03-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための組成物および方法
AR094116A1 (es) 2012-12-20 2015-07-08 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de hdm2
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
DK0585328T3 (da) * 1991-05-22 2002-02-11 Pfizer Substituerede 3-aminoquinuclidiner

Also Published As

Publication number Publication date
MX9301634A (es) 1994-07-29
EP0632809A1 (en) 1995-01-11
ZA932016B (en) 1994-09-22
EP0632809B1 (en) 2001-09-05
FI944394A0 (fi) 1994-09-22
CA2132541C (en) 1997-11-25
PT632809E (pt) 2001-12-28
WO1993019064A1 (en) 1993-09-30
KR950700908A (ko) 1995-02-20
DK0632809T3 (da) 2001-11-12
JPH05320162A (ja) 1993-12-03
CA2132541A1 (en) 1993-09-30
ATE205207T1 (de) 2001-09-15
AU3782493A (en) 1993-10-21
ES2160596T3 (es) 2001-11-16
DE69330714D1 (de) 2001-10-11
IL105098A0 (en) 1993-07-08
JP2656702B2 (ja) 1997-09-24
HU9402745D0 (en) 1994-12-28
DE69330714T2 (de) 2002-02-07
GR3037025T3 (en) 2002-01-31
FI944394A (fi) 1994-09-22
NO943526D0 (no) 1994-09-22

Similar Documents

Publication Publication Date Title
NO943526D0 (no) Kinuklidin-derivater som substans P antagonister
DK0665843T3 (da) Substituerede quinuclidiner som substans P-antagonister
NO854941L (no) Fremgangsmaate for fremstilling av terapeutisk aktive, sure indol-derivater.
HN1998000074A (es) Derivados de macrolidos c-4 sustituidos
RU95104898A (ru) Имидазолсодержащие ингибиторы фарнезид-протеинтрансферазы, способ лечения связанных с ней заболеваний
UY24499A1 (es) Nuevos derivados de 2-(3h)-oxazolona
DE69828197D1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
DK174389D0 (da) Anvendelse af 3-substituerede 2-oxindol-1-carboxamid-forbindelser til fremstilling af farmaceutiske praeparater til inhibering af interleukin-1-biosyntese
SE9902387D0 (sv) New pharmaceutically active compounds
AR020294A1 (es) COMPUESTOS DERIVADOS DE 1-TRIFLUOROMETIL-4-HIDROXI-7-PIPERIDINIL-AMINOMETILCROMANO, COMPOSICION FARMACEUTICA Y USO EN LA PREPARACIoN DE MEDICAMENTOS.
BR9906975A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
SE9802538D0 (sv) New pharmaceutically active compounds
ES2141134T3 (es) Derivados de carbamoil pirrolidona para el tratamiento de la depresion y de los trastornos cerebrovasculares.
ES2168119T3 (es) Derivados de quinoxalina para el tratamiento de tinnitus.
DE59103080D1 (de) 9-Amino-2-phenylbicyclo[3.3.1]nonane und 9-Amino-2-phenylbicyclo[3.3.1]-non-2-ene und diese enthaltende therapeutische Mittel.